The customer obtained false repeat reactive alinity s hiv combo results for 2 samples.The following results were provided: sample id 41413200264: alinity 30.22, 27.13 and 24.56 s/co; wb indeterminate; nat negative sample id 11502931192: alinity 2.31, 2.07 and 2.01 s/co; wb negative/hiv-2 negative; nat negative no impact to patient/donor management was reported.
|
Investigation of the customer's issue included a review of the complaint text, complaint activity, trending data device history and field data.Return testing was not completed as returns were not available.Review of complaint activity and trending reports did not identify any issues or trends related to the complaint issue.Device history review for the reagent lot did not identify any non-conformances, potential non-conformances or deviations.Labeling was reviewed and sufficiently addresses the customer's issue.Review of field data for alinity s hiv ag/ab combo, ln, 6p01-60, lot number 12630be00 showed an initial reactive rate of 0.06% and a repeat reactive rate of 0.04%.Assuming a zero prevalence of hiv infections, the specificity for the field data is calculated to be 99.96%, which met the product requirement.Further, the field data are comparable to study data referenced in the alinity s hiv ag/ab combo package insert, where the specificity was 99.92% with a 95% confidence interval of 99.87% to 99.96%.Based on the investigation, no systemic issue or deficiency of the alinity s hiv ag/ab combo, lot 12603be00 was identified.
|
The customer obtained false repeat reactive alinity s hiv combo results for 2 samples.The following results were provided: sample id (b)(6): alinity 30.22, 27.13 and 24.56 s/co; wb indeterminate; nat negative sample id (b)(6): alinity 2.31, 2.07 and 2.01 s/co; wb negative/hiv-2 negative; nat negative no impact to patient/donor management was reported.
|